On May 12, 2025, President Trump signed an executive order aimed at lowering prescription drug costs in the U.S. by encouraging drug manufacturers to voluntarily reduce prices. While the order acknowledges higher U.S. costs compared to other countries, it lacks a strong enforcement mechanism for compliance. It tasks Health Secretary Robert F. Kennedy Jr. to facilitate consumer purchasing and negotiate for the best prices. However, compliance enforcement appears weak, and it remains unclear whether the administration possesses the legal authority for unilateral actions against noncompliance by pharmaceutical companies.
Trump's executive order asks drugmakers to voluntarily lower pharmaceutical costs for U.S. consumers, but lacks a definitive mechanism for enforcing these reductions.
The order aims to tackle the significant discrepancy in prescription drug prices between the U.S. and other countries, recognizing the burden on American consumers.
Health and Human Services Secretary is directed to facilitate purchasing directly by consumers and negotiate for the lowest prices on behalf of U.S. patients.
Despite its intentions, the order provides limited power to enforce compliance from pharmaceutical companies if they choose not to lower prices.
Collection
[
|
...
]